NASDAQ:NGEN NervGen Pharma Q2 2026 Earnings Results & Report $1.58 +0.02 (+1.28%) As of 10:17 AM Eastern This is a fair market value price provided by Massive. Learn more. NervGen Pharma missed analyst earnings expectations in its Q2 2026 results, released August 13, 2026. The company reported EPS of -$0.37 versus the -$0.09 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 13, 2026TimeBefore Market OpensConference Call9:00 AM ET NervGen Pharma EPS ResultsActual EPS-$0.37Consensus EPS -$0.09Beat/MissMissed by -$0.28One Year Ago EPSN/ANervGen Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (6-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K) NervGen Pharma Q2 2026 Earnings FAQ Did NervGen Pharma beat earnings estimates for Q2 2026? NervGen Pharma (NASDAQ:NGEN) reported earnings of -$0.37 per share for Q2 2026, missing the consensus estimate of -$0.09. The report was announced on Thursday, August 13, 2026. NervGen Pharma Earnings HeadlinesNervGen Pharma : Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord InjuryOctober 12 at 6:01 PM | marketscreener.comMNervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord InjuryOctober 12 at 6:01 PM | finance.yahoo.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 15 at 1:00 AM | Stansberry Research (Ad)NervGen Pharma: The Upside Is Large, But Phase 3 Decides EverythingOctober 1, 2026 | seekingalpha.comNervGen Pharma Corp. (NGEN) Discusses Challenges and Advances in Drug and Therapy Trials for Spinal Cord Injury TranscriptSeptember 30, 2026 | seekingalpha.comNervGen Pharma Corp. (NGEN)September 30, 2026 | finance.yahoo.comSee More NervGen Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like NervGen Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NervGen Pharma and other key companies, straight to your email. Email Address About NervGen PharmaNervGen Pharma (NASDAQ:NGEN) Corp. is a clinical-stage biotechnology company focused on developing therapies that promote repair and recovery in the nervous system. The company’s research is based on the potential to enhance the body’s natural ability to regenerate damaged nerve tissue and restore lost neurological function. NervGen’s lead product candidate, NVG-291, is an investigational peptide designed to stimulate nervous-system repair after injury. The company has been evaluating NVG-291 in clinical development for conditions including spinal cord injury, with additional potential applications in neurological disorders such as multiple sclerosis and peripheral nerve damage. Headquartered in Vancouver, British Columbia, NervGen serves the global biotechnology and healthcare markets through its research and clinical-development programs. The company’s leadership includes President and Chief Executive Officer Mike Kelly. NervGen Pharma trades on the Nasdaq Capital Market under the symbol NGEN and on the Toronto Stock Exchange Venture Exchange under the same symbol.View NervGen Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling?UnitedHealth Beats on Earnings, But Investors Question Growth PathIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
